Roche is to begin a phase 3 trial of its Actemra/RoActemra as a treatment for patients hospitalised with severe COVID-19 pneumonia, following independent research in China suggesting it may help relieve symptoms.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,